MRNA · Moderna, Inc.
$63.32
-0.33 (-0.52%)
At close · Aug 14
Market Cap
$25.28B
Shares
399.24M
Moderna, Inc. Earnings Call Transcripts
Every quarterly earnings call for Moderna, Inc. (MRNA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼32.3%
$3.36B
$1.04B
'22 Q3
22-09-30
▼29.5%
$5.08B
$1.47B
'22 Q4
23-02-23
▼69.3%
$1.86B
$79.00M
'23 Q1
23-05-04
▼92.8%
$344.00M
−$1.38B
'23 Q2
23-08-03
▼45.6%
$1.83B
−$3.63B
'23 Q3
23-11-02
▼44.7%
$2.81B
$217.00M
'23 Q4
24-01-08
▼91%
$167.00M
−$1.18B
'24 Q1
24-05-02
▼29.9%
$241.00M
−$1.28B
'24 Q2
24-08-01
▲1.7%
$1.86B
$13.00M
'24 Q3
24-11-07
▼65.6%
$966.00M
−$1.12B
'24 Q4
25-02-14
▼35.3%
$108.00M
−$971.00M
'25 Q1
25-05-01
▼41.1%
$142.00M
−$825.00M
'25 Q2
25-08-01
▼45.4%
$1.02B
−$200.00M
'25 Q3
25-11-06
▼29.8%
$678.00M
−$826.00M
'25 Q4
26-02-13
▲260.2%
$389.00M
−$1.34B
'26 Q1
26-05-01
LATEST
▲2.1%
$145.00M
−$782.00M
'26 Q2
26-07-31
Earnings call
FY26 · Q2
2026-07-31
Moderna Q2 Earnings call
Positive tone
COVID vaccination rate uncertainty
Financial discipline and cost reduction
Leadership appointments
Revenue
$145.00M
▲ 2.1% YoY Diluted EPS
$-1.97
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference 2026
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-01
Moderna, Inc. Q1 FY2026 Earnings Call
Confident tone
Intismeran oncology pipeline
Q1 financial performance and revenue growth
Pandemic flu mRNA-1018 with BARDA
Revenue
$389.00M
▲ 260.2% YoY Diluted EPS
$-3.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-13
Moderna, Inc. Q4 FY2025 Earnings Call
Balanced tone
Oncology pipeline (INT, mRNA-4259)
COVID franchise and Spikevax/MNEXT Spike
2026 financial outlook
Revenue
$678.00M*
▼ 29.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Moderna, Inc. Q3 FY2025 Earnings Call
Balanced tone
Strategic manufacturing partnerships
Cost reduction and financial discipline
COVID vaccine commercial performance
Revenue
$1.02B
▼ 45.4% YoY Diluted EPS
$-0.51
▼ 1800% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-01
Moderna, Inc. Q2 FY2025 Earnings Call
Balanced tone
Flu and COVID combination pipeline
CMV vaccine program
FDA approvals for commercial products
Revenue
$142.00M
▼ 41.1% YoY Diluted EPS
$-2.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Moderna, Inc. Q1 FY2025 Earnings Call
Balanced tone
Cost reduction and financial discipline
Pipeline and clinical programs
Regulatory and political risk
Revenue
$108.00M
▼ 35.3% YoY Diluted EPS
$-2.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-14
Moderna, Inc. Q4 FY2024 Earnings Call
Balanced tone
Norovirus clinical hold
mRESVIA (RSV) launch and expansion
Financial results and 2024 cost reductions
Revenue
$966.00M*
▼ 65.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Moderna, Inc. Q3 FY2024 Earnings Call
Balanced tone
COVID vaccine market and share
Pipeline / oncology INT program
RSV (mRESVIA)
Revenue
$1.86B
▲ 1.7% YoY Diluted EPS
$0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Moderna, Inc. Q2 FY2024 Earnings Call
Positive tone
COVID-19 franchise and competition
RSV launch (mRESVIA)
Flu and combo vaccines
Revenue
$241.00M
▼ 29.9% YoY Diluted EPS
$-3.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Moderna, Inc. Q1 FY2024 Earnings Call
Positive tone
Late-Stage Pipeline and Clinical Progress
Individualized Neoantigen Therapy (INT)
International RSV and EU Tender
Revenue
$167.00M
▼ 91% YoY Diluted EPS
$-3.07
▼ 1715.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Moderna, Inc. Q4 FY2023 Earnings Call
Balanced tone
Individualized Neoantigen Therapy (INT) oncology program
CMV latent vaccine program
Rare disease programs (Propionic Acidemia, MMA)
Revenue
$2.81B*
▼ 44.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Moderna, Inc. Q3 FY2023 Earnings Call
Revenue
$1.83B
▼ 45.6% YoY Diluted EPS
$-9.53
▼ 476.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Moderna, Inc. Q2 FY2023 Earnings Call
Revenue
$344.00M
▼ 92.8% YoY Diluted EPS
$-3.62
▼ 169.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Moderna, Inc. Q1 FY2023 Earnings Call
Revenue
$1.86B
▼ 69.3% YoY Diluted EPS
$0.19
▼ 97.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Moderna, Inc. Q4 FY2022 Earnings Call
Revenue
$5.08B*
▼ 29.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Moderna, Inc. Q3 FY2022 Earnings Call
Revenue
$3.36B
▼ 32.3% YoY Diluted EPS
$2.53
▼ 67.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Moderna, Inc. Q2 FY2022 Earnings Call
Revenue
$4.75B
▲ 9.1% YoY Diluted EPS
$5.24
▼ 18.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Moderna, Inc. Q1 FY2022 Earnings Call
Revenue
$6.07B
▲ 213.2% YoY Diluted EPS
$8.58
▲ 202.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Moderna, Inc. Q4 FY2021 Earnings Call
Revenue
$7.21B*
▲ 1162.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Moderna, Inc. Q3 FY2021 Earnings Call
Revenue
$4.97B
▲ 3065% YoY Diluted EPS
$7.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Moderna, Inc. Q2 FY2021 Earnings Call
Revenue
$4.35B
▲ 6398.5% YoY Diluted EPS
$6.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Moderna, Inc. Q1 FY2021 Earnings Call
Revenue
$1.94B
▲ 24112.5% YoY Diluted EPS
$2.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Moderna, Inc. Q4 FY2020 Earnings Call
Revenue
$571.00M*
▲ 3962.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Moderna, Inc. Q3 FY2020 Earnings Call
Revenue
$157.00M
▲ 821% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Moderna, Inc. Q2 FY2020 Earnings Call
Revenue
$67.00M
▲ 412.1% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Moderna, Inc. Q1 FY2020 Earnings Call
Revenue
$8.00M
▼ 50.1% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Moderna, Inc. Q4 FY2019 Earnings Call
Revenue
$14.05M
▼ 60.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1682852
CUSIP
60770K107
13F (30d)
727 filings
689 filers
Visit website
Investor relations